1. Home
  2. COGT vs FLYW Comparison

COGT vs FLYW Comparison

Compare COGT & FLYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • FLYW
  • Stock Information
  • Founded
  • COGT 2014
  • FLYW 2009
  • Country
  • COGT United States
  • FLYW United States
  • Employees
  • COGT N/A
  • FLYW N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • FLYW Computer Software: Prepackaged Software
  • Sector
  • COGT Health Care
  • FLYW Technology
  • Exchange
  • COGT Nasdaq
  • FLYW Nasdaq
  • Market Cap
  • COGT 1.1B
  • FLYW 1.2B
  • IPO Year
  • COGT 2018
  • FLYW 2021
  • Fundamental
  • Price
  • COGT $12.07
  • FLYW $11.69
  • Analyst Decision
  • COGT Strong Buy
  • FLYW Buy
  • Analyst Count
  • COGT 9
  • FLYW 16
  • Target Price
  • COGT $20.25
  • FLYW $16.21
  • AVG Volume (30 Days)
  • COGT 5.0M
  • FLYW 2.1M
  • Earning Date
  • COGT 08-05-2025
  • FLYW 08-05-2025
  • Dividend Yield
  • COGT N/A
  • FLYW N/A
  • EPS Growth
  • COGT N/A
  • FLYW N/A
  • EPS
  • COGT N/A
  • FLYW 0.04
  • Revenue
  • COGT N/A
  • FLYW $511,493,000.00
  • Revenue This Year
  • COGT N/A
  • FLYW $18.35
  • Revenue Next Year
  • COGT N/A
  • FLYW $15.17
  • P/E Ratio
  • COGT N/A
  • FLYW $325.65
  • Revenue Growth
  • COGT N/A
  • FLYW 20.97
  • 52 Week Low
  • COGT $3.72
  • FLYW $8.20
  • 52 Week High
  • COGT $12.97
  • FLYW $23.40
  • Technical
  • Relative Strength Index (RSI)
  • COGT 78.82
  • FLYW 56.28
  • Support Level
  • COGT $11.93
  • FLYW $10.68
  • Resistance Level
  • COGT $12.79
  • FLYW $11.92
  • Average True Range (ATR)
  • COGT 0.74
  • FLYW 0.41
  • MACD
  • COGT 0.03
  • FLYW 0.00
  • Stochastic Oscillator
  • COGT 76.56
  • FLYW 67.33

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

Share on Social Networks: